SAN DIEGO, July 6, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Joann V. Lofgren to the newly created position of Vice President of Market Development, effective July 6, 2015. In this role, Ms. Lofgren will be responsible for evaluating, designing, and executing on the company's market and product development strategy for all therapeutic products.
"I'm very excited to welcome Joann to the OncoSec team and have her lead the marketing and product development efforts for the company," said Punit Dhillon, President and CEO of OncoSec. "With extensive medical device marketing experience, Joann has a proven track record for building and commercializing products and therapies in the healthcare industry that help provide long-term benefits for patients. Joann's market and industry insights will be valuable additions as we continue to advance our immuno-oncology clinical pipeline."
Most recently, Ms. Lofgren served as the Marketing Director for Hansen Medical, where she developed and implemented strategic plans to grow the sales of robotic systems and catheters in the $1.5 billion global electrophysiology ablation market. Prior to joining Hansen Medical, Ms. Lofgren served as Group Marketing Manager at Abbott Vascular, a division of Abbott, a diversified global healthcare company. While at Abbott Vascular, she managed a commercial team responsible for its $1.5 billion global interventional cardiology product portfolio and created a long-term product portfolio plan to maximize commercial opportunity while gaining operational efficiency.
Ms. Lofgren earned a bachelor's degree in bioengineering from the University of California, San Diego and a master's degree in entrepreneurship and marketing from the University of California, Los Angeles' Anderson School of Management.
About OncoSec Medical Inc. OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse™ IL-12 have demonstrated an acceptable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma and squamous cell carcinoma of the head and neck. In addition to ImmunoPulse™ IL-12, the company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
CONTACT: Investor Relations: Jordyn Kopin OncoSec Medical Inc. 855-662-6732 firstname.lastname@example.org
Media Relations: Mary Marolla OncoSec Medical Inc. 855-662-6732 email@example.com
SOURCE OncoSec Medical Inc.